Jpmorgan Chase & CO Cue Biopharma, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,051 shares of CUE stock, worth $872. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,051

Previous 1,062 1.04%

Holding current value

$872

Previous $1,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$0.91 - $1.75 $10 - $19	-11 Reduced 1.04%	1,051 $0
Q4 2024 Feb 12, 2025	BUY	$0.71 - $1.88 $112 - $297	158 Added 17.48%	1,062 $1,000
Q2 2024 Aug 12, 2024	SELL	$1.24 - $2.18 $18,007 - $31,657	-14,522 Reduced 94.14%	904 $1,000
Q1 2024 Dec 26, 2024	BUY	$1.77 - $3.09 $25,703 - $44,872	14,522 Added 1606.42%	15,426 $29,000
Q1 2024 May 10, 2024	SELL	$1.77 - $3.09 $12,416 - $21,676	-7,015 Reduced 31.26%	15,426 $29,000
Q4 2023 Dec 26, 2024	BUY	$1.72 - $3.1 $37,043 - $66,764	21,537 Added 2382.41%	22,441 $59,000
Q3 2023 Nov 14, 2023	SELL	$2.23 - $4.69 $11,462 - $24,106	-5,140 Reduced 18.64%	22,441 $51,000
Q2 2023 Aug 11, 2023	BUY	$3.11 - $4.91 $85,655 - $135,231	27,542 Added 70620.51%	27,581 $100,000
Q2 2022 Aug 11, 2022	SELL	$2.49 - $5.92 $36,234 - $86,147	-14,552 Reduced 99.73%	39 $0
Q1 2022 May 11, 2022	BUY	$4.41 - $12.28 $11,227 - $31,264	2,546 Added 21.14%	14,591 $71,000
Q4 2021 Feb 10, 2022	BUY	$10.86 - $17.85 $5,538 - $9,103	510 Added 4.42%	12,045 $136,000
Q3 2021 Nov 12, 2021	BUY	$10.06 - $15.3 $116,042 - $176,485	11,535 New	11,535 $168,000

Others Institutions Holding CUE

# of Institutions

Shares Held

14.9M

Call Options Held

10.1K

Put Options Held

1.4K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $29.4M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Cue Biopharma, Inc. Transaction History